Evidence map›Paper›PMID 34657380›Full record

ArticleCancer communications (London, England)2021

Phospholipase iPLA2β acts as a guardian against ferroptosis.

Chao Mao, Guang Lei, Li Zhuang, Boyi Gan

Abstract readEditorial
In one paragraph

Article in Cancer communications (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. The Phospholipase AJournal of lipid and atherosclerosis · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Cellular metabolism: A key player in cancer ferroptosis.Cancer communications (London, England) · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chao MaoDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-8685-8539
Guang LeiDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-3282-0666
Li ZhuangDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Boyi GanDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-8884-6040

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Studying metabolic stress signaling in renal cancerR01CA181196 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAN, BOYI · 2014 to 2024
$3.4M
Targeting SLC7A11-induced nutrient dependency in cancer: mechanisms and preclinical translationR01CA244144 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAN, BOYI · 2020 to 2024
$2.1M
Targeting ferroptosis in radioresistance in lung cancer: mechanisms and preclinical translationR01CA247992 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAN, BOYI · 2021 to 2025
$1.9M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA181196NCI NIH HHS R01 CA244144NCI NIH HHS R01 CA247992NIH HHS R01CA181196NIH HHS R01CA244144NIH HHS R01CA247992
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FerroptosisHumansPhospholipasesPhospholipases

Identifiers

PMID34657380
PMCPMC8626608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.